# GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds

> **NCT02260609** · PHASE4 · COMPLETED · sponsor: **Osiris Therapeutics** · enrollment: 31 (actual)

## Conditions studied

- Complex Diabetic Foot Wounds

## Interventions

- **OTHER:** Grafix®

## Key facts

- **NCT ID:** NCT02260609
- **Lead sponsor:** Osiris Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-10
- **Final completion:** —
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2016-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260609, "GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02260609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*